Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23922794 | 0.84 | KDM4E (0.47) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL28833166 | 0.84 | KDM4E (0.43) | KDM4ESMN1; SMN2CA12CA1CA2 | |
| SCHEMBL28833157 | 0.81 | KDM4E (0.42) | KDM4ESMN1; SMN2CA12CA1CA2 | |
| SCHEMBL23421705 | 0.81 | KDM4E (0.42) | KDM4ESMN1; SMN2CA12CA1CA2 | |
| SCHEMBL16852808 | 0.79 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9207480 | 0.73 | KDM4E (0.56) | KDM4ESMN1; SMN2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL23923170 | 0.72 | KDM4E (0.47) | KDM4ESMN1; SMN2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL21686085 | 0.70 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9267870 | 0.70 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2827984 | 0.69 | ALDH1A1 (0.59) | KDM4EALDH1A1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448377-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-21 | — | — | US | disclosed |
| EP-4066893-B1 | 6,7,8,9-TETRAHYDRO-4H-QUINOLIZIN-4-ONE COMPOUND AS OREXIN TYPE 2 RECEPTOR AGONIST | TAKEDA PHARMACEUTICALS CO (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-12071434-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-27 | — | — | US | disclosed |
| EP-3895707-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-10-04 | — | — | EP | disclosed |
| US-20230037557-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-09 | — | — | US | disclosed |
| US-20230042358-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-09 | — | — | US | disclosed |
| EP-4066893-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-10-05 | — | — | EP | disclosed |
| CN-115003670-A | Heterocyclic compounds | 武田药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448377-B2 | Heterocyclic compound | HCRTR2, HCRTR1, NTSR2 | KDM4E 1355/4885SMN1; SMN2 1031/4885CA12 2119/4885 |
| US-20230042358-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NTSR2 | KDM4E 1355/4885SMN1; SMN2 1031/4885CA12 2119/4885 |
| US-12071434-B2 | Heterocyclic compound | HCRTR2, HCRTR1, NTSR2 | KDM4E 1355/4885SMN1; SMN2 1031/4885CA12 2119/4885 |
| US-20230037557-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NTSR2 | KDM4E 1355/4885SMN1; SMN2 1031/4885CA12 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.